Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

499P - Heterogeneity in the immune inflamed biomarkers of MSS and MSI colorectal cancer

Date

17 Sep 2020

Session

E-Poster Display

Topics

Tumour Site

Colon and Rectal Cancer

Presenters

Iosune Baraibar Argota

Citation

Annals of Oncology (2020) 31 (suppl_4): S409-S461. 10.1016/annonc/annonc270

Authors

I. Baraibar Argota1, C. Rubio-Pérez2, G. Argiles Martinez1, F.J. Ros Montañá1, F. Salvà1, N. Mulet Margalef3, J.L. Cuadra Urteaga1, D.H. Marmolejo Castaneda1, N. Saoudi Gonzalez1, D. Ciardiello2, J. Tabernero1, J. Seoane2, E. Elez1

Author affiliations

  • 1 Medical Oncology, Vall d'Hebron University Hospital, 08035 - Barcelona/ES
  • 2 Icrea, Translational Research Dept., Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, 8035 - Barcelona/ES
  • 3 Dept. Medical Oncology, Institut Català d'Oncologia-Hospital Duran i Reynals, 08907 - Hospitalet de Llobregat/ES

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 499P

Background

MSI status in metastatic colorectal cancer (mCRC) is associated with benefit from immune checkpoint inhibitors (ICI). However, this biomarker needs to be refined towards a better patient selection. Other biomarkers besides MSI have been explored, including high PD-L1 expression in tumor cells or tumor infiltrating immune cells, high prevalence of tumor-infiltrating lymphocytes and B cells, IFN-g signatures and high tumor mutational burden. Here we explore the immune cell landscape and inflamed biomarkers in MSS and MSI primary colorectal tumors and metastatic lesions.

Methods

We downloaded The Cancer Genome Atlas colorectal RNA-seq data (RPKM) and MSI status from cBioportal (Cerami et al 2012). The abundance of 64 distinct immune or stromal cell types was inferred through xCell (Aran et al 2017). xCell outperforms methods to portrait tumoral cell infiltration by learning from the expression profiles of thousands of pure cell types and validating the signatures through in-silico simulations and flow cytometry phenotyping. IFN-g signature (6 genes) was calculated as specified in Ayers et al 2017.

Results

MSI colorectal tumors tended to present high expression of PD-L1, an IFN-g signature and CD8+ Tcell infiltration, in contrast to MSS cases (p < 0.001). However, CD8+Tcell infiltration and high levels of IFN-g signature were not constant in MSI tumors, while some MSS tumors presented an IFN-g signature and high PD-L1 expression. Interestingly, some MSI tumors showed high presence of myeloid cells (p < 0.001) and B cells were present in the tumors presenting high levels of CD8 T cell infiltration but also in some MSS tumors with low CD8 T cell infiltration. An important group of MSS tumors showed high infiltration on NK cells (p < 0.001). Presence of endothelial cells was independent of microsatellite status, although there was an increased presence of fibroblasts in the MSS tumors (p = 0.012).

Conclusions

MSI status is not an optimal biomarker to classify inflamed mCRC. These tumors present a complex inmune-biology which includes multiple immune-phenotypes that could be responsible for the diversity on immune-responses in MSI and MSS mCRC. The implementation of multiomic approach is necessary to improve clinical efficacy of cancer inmunotherapy in mCRC.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

I. Baraibar Argota: Honoraria (self): Sanofi; Travel/Accommodation/Expenses: Amgen. G. Argiles Martinez: Advisory/Consultancy: Roche, Bristol-Myers Squibb, ; Advisory/Consultancy: Genentech/Roche, ; Advisory/Consultancy: Bayer; Advisory/Consultancy: Servier; Travel/Accommodation/Expenses: Bayer; Travel/Accommodation/Expenses: Roche; Travel/Accommodation/Expenses: Amgen; Travel/Accommodation/Expenses: Servier. F.J. Ros Montañá: Honoraria (self): Sanofi; Travel/Accommodation/Expenses: Amgen. J.L. Cuadra Urteaga: Advisory/Consultancy, Travel/Accommodation/Expenses: Hoffman La-Roche; Advisory/Consultancy, Travel/Accommodation/Expenses: Amgen; Advisory/Consultancy, Travel/Accommodation/Expenses: Merck Serono; Advisory/Consultancy, Travel/Accommodation/Expenses: Lilly; Advisory/Consultancy, Travel/Accommodation/Expenses: Sanofi. J. Tabernero: Advisory/Consultancy: Array Biopharma; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Bayer; Advisory/Consultancy: BeiGene; Advisory/Consultancy: Boehringer Ingelheim; Advisory/Consultancy: Merck Serono; Advisory/Consultancy: Chugai; Advisory/Consultancy: Merrimack; Advisory/Consultancy: Merus; Advisory/Consultancy: Molecular Part; Advisory/Consultancy: Genentech, Inc.; Advisory/Consultancy: Ipsen; Advisory/Consultancy: Genmab A/S; Advisory/Consultancy: Kura Oncology; Advisory/Consultancy: Lilly; Advisory/Consultancy: Menarini; Advisory/Consultancy: MSD; Advisory/Consultancy: Halozyme; Advisory/Consultancy: Imugene Limited; Advisory/Consultancy: Inflection Biosciences Limited. J. Seoane: Advisory/Consultancy, Research grant/Funding (self): Mosaic Biomedicals; Leadership role: Northern Biologicals; Research grant/Funding (self): Roche Glycart AG; Research grant/Funding (self): Ridgeline; Research grant/Funding (self): Isarna Therapeutics; Research grant/Funding (self): Hoffmann-La Roche LTD. E. Elez: Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Hoffman La - Roche; Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Servier, Amgen; Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Array Biopharma; Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Sanofi; Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Merck Sharp & Dohme Corp.; Honoraria (institution): Array Biopharma; Honoraria (institution): Boehringer Ingelheim; Honoraria (institution): Hoffman La-Roche; Honoraria (institution): Merck Sharp & Dohme Corp.; Honoraria (institution): Bristol Myers Squibb; Honoraria (institution): Abbvie, Amgen; Honoraria (institution): Novartis; Honoraria (institution): GlaxoSmithKline; Honoraria (institution): Astrazeneca; Research grant/Funding (institution): Merck Sharp & Dohme Corp.; Research grant/Funding (institution): Sanofi. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.